1. Remote ischemic conditioning for acute ischemic stroke part 2: Study protocol for a randomized controlled trial
- Author
-
Kentaro Ishizuka, Takao Hoshino, Sono Toi, Takafumi Mizuno, Megumi Hosoya, Moeko Saito, Yasuto Sato, Yoshiki Yagita, Kenichi Todo, Manabu Sakaguchi, Takashi Ohashi, Kenji Maruyama, Shuji Hino, Yutaka Honma, Ryosuke Doijiri, Hiroshi Yamagami, Yasuyuki Iguchi, Teruyuki Hirano, Kazumi Kimura, Takanari Kitazono, and Kazuo Kitagawa
- Subjects
acute ischemic stroke ,remote ischemic conditioning (RIC) ,neurological severity ,good functional outcome ,randomized controlled trial ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
BackgroundRemote ischemic conditioning (RIC) refers to the application of repeated short periods of ischemia intended to protect remote areas against tissue damage during and after prolonged ischemia.AimWe aim to evaluate the efficacy of RIC, determined by the modified Rankin Scale (mRS) score at 90 days after stroke onset.Design and methodsThis study is an investigator-initiated, multicenter, prospective, randomized, open-label, parallel-group clinical trial. The sample size is 400, comprising 200 patients who will receive RIC and 200 controls. The patients will be divided into three groups according to their National Institutes of Health Stroke Scale score at enrollment: 5–9, mild; 10–14, moderate; 15–20, severe. The RIC protocol will be comprised of four cycles, each consisting of 5 min of blood pressure cuff inflation (at 200 mmHg or 50 mmHg above the systolic blood pressure) followed by 5 min of reperfusion, with the cuff placed on the thigh on the unaffected side. The control group will only undergo blood pressure measurements before and after the intervention period. This trial is registered with the UMIN Clinical Trial Registry (https://www.umin.ac.jp/: UMIN000046225).Study outcomeThe primary outcome will be a good functional outcome as determined by the mRS score at 90 days after stroke onset, with a target mRS score of 0–1 in the mild group, 0–2 in the moderate group, and 0–3 in the severe group.DiscussionThis trial may help determine whether RIC should be recommended as a routine clinical strategy for patients with ischemic stroke.
- Published
- 2022
- Full Text
- View/download PDF